Celgene price hikes on Revlimid tied to political advertising by Menendez campaign

Celgene price hikes on Revlimid tied to political advertising by Menendez campaign The passage links a pharmaceutical company's aggressive drug price increases in 2017 to a Senate campaign’s advertising strategy, suggesting possible lobbying or financial influence. It provides specific dates, drug names, price figures, and mentions a political figure (Sen. Menendez) and a corporate executive (Mr. Hugin). While the connection is indirect and unverified, it offers a concrete avenue for investigating pharma‑politics financial flows and potential misconduct. Key insights: Celgene raised Revlimid price by ~20% in 2017, the third increase that year.; The price hike coincided with the scrapping of a Crohn's disease drug program.; Sen. Menendez's campaign intensified ads accusing Mr. Hugin of profit‑driven price hikes.